SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MEDX ... anybody following?
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2240 62 0 MEDX
Emcee:  Ed Offstein Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1565I wonder about enrollment for this trial. How many advanced CLL patients haven&tuck-12/11/2006
1564GENMAB INITIATES HUMAX-CD20 FRONT LINE CLL STUDY Copenhagen, Denmark; December Icebrg-12/11/2006
1563GENMAB ANNOUNCES EARLY RESULTS OF ONGOING HUMAX-CD4 TRIALS Copenhagen, Denmark;Icebrg-12/10/2006
1562J&J to take short break in enrollment of subjects in trial of arthritis drugIcebrg-12/8/2006
1561Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment oIcebrg-12/7/2006
1560Schering-Plough drug trial suspended - analyst Wed Dec 6, 2006 10:51am ET30 SchIcebrg-12/6/2006
1559Ex-biotech CEO also quits state panel Stock-option probe led to Medarex exit WedIcebrg-12/6/2006
1558Genmab Announces Positive Interim Data for the HuMax-CD20 Phase II RA Study COPEnigel bates-12/5/2006
1557Big hole in development pipeline Robin Pagnamenta: Analysis The unexpected loss Icebrg-12/5/2006
1556Moores UCSD Cancer Center Announces Cancer Therapeutics Development Agreement MoIcebrg-12/5/2006
1555MDX-1100, A FULLY HUMAN ANTI-CXCL10 (IP-10) ANTIBODY, IS A HIGH AFFINITY, NEUTRAIcebrg-12/3/2006
1554[Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody tuck-12/3/2006
1553Its great that we are learning more and more preclinical information about ipiliTettra-12/3/2006
1552CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of Icebrg-12/2/2006
1551Chuckle. It's faintly absurd to suggest that the options thing will have annigel bates-12/2/2006
1550<i>No takeover as long as options scandal clouds MEDX</i> A brilliaIcebrg-12/2/2006
1549No takeover as long as options scandal clouds MEDX. Possible delisting still neMaven1-12/1/2006
1548<i>But there are still lots of big pharma who have no date for the Prom. A.J. Mullen-12/1/2006
1547Genmab Up 5.9% On Takeover Talk >GEN.KO Friday, December 01, 2006 7:52:45 AMIcebrg-12/1/2006
1546Ashley, You make a good point about the difficulties that come up in buying outIRWIN JAMES FRANKEL-12/1/2006
1545It's unclear whether AZN was liable to pay compensation for ditching the agrA.J. Mullen-12/1/2006
1544AZN seem to have ditched ABGX - Message 22983958nigel bates-12/1/2006
1543I vaguely remember one biotech that had its partnership handed back to them whenA.J. Mullen-12/1/2006
1542Wasn't an obvious issue with Abgenix. It's probably more of an issue fonigel bates-12/1/2006
1541Straight-forward licensing adds value, as do joint-developments. But does the vA.J. Mullen-11/30/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News